Recordati Expands Into Rare Cancer Space With EUSA Pharma Buy
The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.
The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.